101
|
Affolder T, Akimoto H, Akopian A, Albrow MG, Amaral P, Amendolia SR, Amidei D, Anikeev K, Antos J, Apollinari G, Arisawa T, Asakawa T, Ashmanskas W, Atac M, Azfar F, Azzi-Bacchetta P, Bacchetta N, Bailey MW, Bailey S, de Barbaro P, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barone M, Bauer G, Bedeschi F, Belforte S, Bellettini G, Bellinger J, Benjamin D, Bensinger J, Beretvas A, Berge JP, Berryhill J, Bertolucci S, Bevensee B, Bhatti A, Bigongiari C, Binkley M, Bisello D, Blair RE, Blocker C, Bloom K, Blumenfeld B, Blusk SR, Bocci A, Bodek A, Bokhari W, Bolla G, Bonushkin Y, Bortoletto D, Boudreau J, Brandl A, van den Brink S, Bromberg C, Brozovic M, Bruner N, Buckley-Geer E, Budagov J, Budd HS, Burkett K, Busetto G, Byon-Wagner A, Byrum KL, Campbell M, Caner A, Carithers W, Carlson J, Carlsmith D, Cassada J, Castro A, Cauz D, Cerri A, Chan AW, Chang PS, Chang PT, Chapman J, Chen C, Chen YC, Cheng MT, Chertok M, Chiarelli G, Chirikov-Zorin I, Chlachidze G, Chlebana F, Christofek L, Chu ML, Cihangir S, Ciobanu CI, Clark AG, Connolly A, Conway J, Cooper J, Cordelli M, Costanzo D, Cranshaw J, Cronin-Hennessy D, Cropp R, Culbertson R, Dagenhart D, DeJongh F, Dell’Agnello S, Dell’Orso M, Demina R, Demortier L, Deninno M, Derwent PF, Devlin T, Dittmann JR, Donati S, Done J, Dorigo T, Eddy N, Einsweiler K, Elias JE, Engels E, Erdmann W, Errede D, Errede S, Fan Q, Feild RG, Ferretti C, Fiori I, Flaugher B, Foster GW, Franklin M, Freeman J, Friedman J, Fukui Y, Galeotti S, Gallinaro M, Gao T, Garcia-Sciveres M, Garfinkel AF, Gatti P, Gay C, Geer S, Gerdes DW, Giannetti P, Giromini P, Glagolev V, Gold M, Goldstein J, Gordon A, Goshaw AT, Gotra Y, Goulianos K, Grassmann H, Green C, Groer L, Grosso-Pilcher C, Guenther M, Guillian G, Guimaraes da Costa J, Guo RS, Haber C, Hafen E, Hahn SR, Hall C, Handa T, Handler R, Hao W, Happacher F, Hara K, Hardman AD, Harris RM, Hartmann F, Hatakeyama K, Hauser J, Heinrich J, Heiss A, Herndon M, Hinrichsen B, Hoffman KD, Holck C, Hollebeek R, Holloway L, Hughes R, Huston J, Huth J, Ikeda H, Incandela J, Introzzi G, Iwai J, Iwata Y, James E, Jensen H, Jones M, Joshi U, Kambara H, Kamon T, Kaneko T, Karr K, Kasha H, Kato Y, Keaffaber TA, Kelley K, Kelly M, Kennedy RD, Kephart R, Khazins D, Kikuchi T, Kirk M, Kim BJ, Kim HS, Kim MJ, Kim SH, Kim YK, Kirsch L, Klimenko S, Koehn P, Köngeter A, Kondo K, Konigsberg J, Kordas K, Korn A, Korytov A, Kovacs E, Kroll J, Kruse M, Kuhlmann SE, Kurino K, Kuwabara T, Laasanen AT, Lai N, Lami S, Lammel S, Lamoureux JI, Lancaster M, Latino G, LeCompte T, Lee AM, Leone S, Lewis JD, Lindgren M, Liss TM, Liu JB, Liu YC, Lockyer N, Loken J, Loreti M, Lucchesi D, Lukens P, Lusin S, Lyons L, Lys J, Madrak R, Maeshima K, Maksimovic P, Malferrari L, Mangano M, Mariotti M, Martignon G, Martin A, Matthews JAJ, Mayer J, Mazzanti P, McFarland KS, McIntyre P, McKigney E, Menguzzato M, Menzione A, Mesropian C, Miao T, Miller R, Miller JS, Minato H, Miscetti S, Mishina M, Mitselmakher G, Moggi N, Moore E, Moore R, Morita Y, Mukherjee A, Muller T, Munar A, Murat P, Murgia S, Musy M, Nachtman J, Nahn S, Nakada H, Nakaya T, Nakano I, Nelson C, Neuberger D, Newman-Holmes C, Ngan CYP, Nicolaidi P, Niu H, Nodulman L, Nomerotski A, Oh SH, Ohmoto T, Ohsugi T, Oishi R, Okusawa T, Olsen J, Pagliarone C, Palmonari F, Paoletti R, Papadimitriou V, Pappas SP, Partos D, Patrick J, Pauletta G, Paulini M, Paus C, Pescara L, Phillips TJ, Piacentino G, Pitts KT, Plunkett R, Pompos A, Pondrom L, Pope G, Popovic M, Prokoshin F, Proudfoot J, Ptohos F, Punzi G, Ragan K, Rakitine A, Reher D, Reichold A, Riegler W, Ribon A, Rimondi F, Ristori L, Robertson WJ, Robinson A, Rodrigo T, Rolli S, Rosenson L, Roser R, Rossin R, Sakumoto WK, Saltzberg D, Sansoni A, Santi L, Sato H, Savard P, Schlabach P, Schmidt EE, Schmidt MP, Schmitt M, Scodellaro L, Scott A, Scribano A, Segler S, Seidel S, Seiya Y, Semenov A, Semeria F, Shah T, Shapiro MD, Shepard PF, Shibayama T, Shimojima M, Shochet M, Siegrist J, Signorelli G, Sill A, Sinervo P, Singh P, Slaughter AJ, Sliwa K, Smith C, Snider FD, Solodsky A, Spalding J, Speer T, Sphicas P, Spinella F, Spiropulu M, Spiegel L, Stanco L, Steele J, Stefanini A, Strologas J, Strumia F, Stuart D, Sumorok K, Suzuki T, Takano T, Takashima R, Takikawa K, Tamburello P, Tanaka M, Tannenbaum B, Taylor W, Tecchio M, Teng PK, Terashi K, Tether S, Theriot D, Thurman-Keup R, Tipton P, Tkaczyk S, Tollefson K, Tollestrup A, Toyoda H, Trischuk W, de Troconiz JF, Tseng J, Turini N, Ukegawa F, Valls J, Vejcik S, Velev G, Vidal R, Vilar R, Volobouev I, Vucinic D, Wagner RG, Wagner RL, Wahl J, Wallace NB, Walsh AM, Wang C, Wang CH, Wang MJ, Watanabe T, Waters D, Watts T, Webb R, Wenzel H, Wester WC, Wicklund AB, Wicklund E, Williams HH, Wilson P, Winer BL, Winn D, Wolbers S, Wolinski D, Wolinski J, Wolinski S, Worm S, Wu X, Wyss J, Yagil A, Yao W, Yeh GP, Yeh P, Yoh J, Yosef C, Yoshida T, Yu I, Yu S, Zanetti A, Zetti F, Zucchelli S. Measurement of the differential dijet mass cross section inpp¯collisions ats=1.8TeV. Int J Clin Exp Med 2000. [DOI: 10.1103/physrevd.61.091101] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
102
|
Lefrère JJ, Lerable J, Mariotti M, Bogard M, Thibault V, Frangeul L, Loiseau P, Bouchardeau F, Laperche S, Pawlotsky JM, Cantaloube JF, Biagini P, de Lamballerie X, Izopet J, Defer C, Lepot I, Poveda JD, Dussaix E, Gerolami V, Halfon P, Buffet-Janvresse C, Férec C, Mercier B, Marcellin P, Martinot-Peignoux M, Gassain M. Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction assay. J Virol Methods 2000; 85:117-24. [PMID: 10716345 DOI: 10.1016/s0166-0934(99)00160-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The aim of this study was to determine whether multicentre quality controls for the detectability of viral genomes could contribute to the improvement of diagnostic performance in the participating laboratories. The study was carried out during two successive rounds, during which 18 laboratories specialized in nucleic acid testing analyzed, through a polymerase chain reaction (PCR) assay, a common panel of GB virus C (GBV-C)/hepatitis G virus (HGV) RNA-positive and -negative samples. During the first round, the laboratories used either an 'in-house' PCR procedure or a partly standardized commercial test. After decoding the results of the first round, the procedures of the participating laboratories were compared in order to establish a consensus procedure deduced from those of the laboratories which provided the best results. During the second round, each participating laboratory could use the resulting consensus procedure, or its own procedure, or both. The results of this quality control study indicated that, whatever method used, even specialized and trained laboratories may give false-negative or false-positive results. The commercial assay did not guarantee a systematic high quality level of results. The striking heterogeneity of results observed among laboratories using the same commercial assay confirm that molecular biology methods need skilled technicians. The results of this quality control study suggest that full standardization of viral genome detection, including all steps of the procedure, is necessary and that the laboratories performing PCR should participate in repeated quality control studies, whatever technique is being used.
Collapse
|
103
|
Lefrère JJ, Roudot-Thoraval F, Lefrère F, Kanfer A, Mariotti M, Lerable J, Thauvin M, Lefèvre G, Rouger P, Girot R. Natural history of the TT virus infection through follow-up of TTV DNA-positive multiple-transfused patients. Blood 2000; 95:347-51. [PMID: 10607723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
Little is known about the natural history and the pathogenicity of the TT virus (TTV). We present our findings of a cross-sectional study based on the TTV DNA screening of 173 multiple-transfused patients and a longitudinal study based on the follow-up of TTV DNA-positive patients. Overall, 48 patients (27.7%) tested positive for TTV DNA. The influence of the number of blood donor exposures on the prevalence of blood-borne viral infection indicates that TTV, hepatitis C virus (HCV), and an RNA virus known as GB virus C/hepatitis G virus (GBV-C/HGV) share a parenteral transmission, but that TTV, in contrast to the 2 other viruses, is also transmitted by at least another efficient means. The patients having a well-defined date of TTV infection were positive for TTV DNA during a mean period of 3.1 years. A chronic infection was observed in 31 cases (86%). TTV carriage appeared clinically benign in all patients. No clinical evidence of a disease potentially linked to the TTV infection was observed in patients with TTV DNA carriage over several years. The majority of TTV carriers had no biochemical evidence of liver disease. The prevalence of elevated serum alanine aminotransferase (ALT) level was higher in the TTV DNA-positive group, even in the absence of HCV infection, but the observed peaks of ALT level were most often transient and very mild. The prevalence of TTV DNA observed in blood recipients is consistent with that of TTV infection observed in blood donors. TTV infection frequently tends to persist. (Blood. 2000;95:347-351)
Collapse
|
104
|
Abe F, Albrow MG, Amendolia SR, Amidei D, Antos J, Anway-Wiese C, Apollinari G, Areti H, Atac M, Auchincloss P, Azfar F, Azzi P, Bacchetta N, Badgett W, Bailey MW, Bao J, de Barbaro P, Barbaro-Galtieri A, Barnes VE, Barnett BA, Bartalini P, Bauer G, Baumann T, Bedeschi F, Behrends S, Belforte S, Bellettin G, Bellinger J, Benjamin D, Benlloch J, Bensinger J, Benton D, Beretvas A, Berge JP, Bertolucci S, Bhatti A, Biery K, Binkley M, Bird F, Bisello D, Blair RE, Blocker C, Bodek A, Bokhari W, Bolognesi V, Bortoletto D, Boswell C, Boulos T, Brandenburg G, Bromberg C, Buckley-Geer E, Budd HS, Burkett K, Busetto G, Byon-Wagner A, Byrum KL, Cammerata J, Campagnari C, Campbell M, Caner A, Carithers W, Carlsmith D, Castro A, Cen Y, Cervelli F, Chao HY, Chapman J, Cheng MT, Chiarelli G, Chikamatsu T, Chiou CN, Christofek L, Cihangir S, Clark AG, Cobal M, Contreras M, Conway J, Cooper J, Cordelli M, Couyoumtzelis C, Crane D, Cunningham JD, Daniels T, DeJongh F, Delchamps S, Dell’Agnello S, Dell’Orso M, Demortier L, Denby B, Deninno M, Derwent PF, Devlin T, Dickson M, Dittmann JR, Donati S, Drucker RB, Dunn A, Einsweiler K, Elias JE, Ely R, Engels E, Eno S, Errede D, Errede S, Fan Q, Farhat B, Fiori I, Flaugher B, Foster GW, Franklin M, Frautschi M, Freeman J, Friedman J, Frisch H, Fry A, Fuess TA, Fukui Y, Funaki S, Gagliardi G, Galeotti S, Gallinaro M, Garfinkel AF, Geer S, Gerdes DW, Giannetti P, Giokaris N, Giromini P, Gladney L, Glenzinski D, Gold M, Gonzalez J, Gordon A, Goshaw AT, Goulianos K, Grassmann H, Grewal A, Groer L, Grosso-Pilcher C, Haber C, Hahn SR, Hamilton R, Handler R, Hans RM, Hara K, Harral B, Harris RM, Hauger SA, Hauser J, Hawk C, Heinrich J, Cronin-Hennessy D, Hollebeek R, Holloway L, Hölscher A, Hong S, Houk G, Hu P, Huffman BT, Hughes R, Hurst P, Huston J, Huth J, Hylen J, Incagli M, Incandela J, Iso H, Jensen H, Jessop CP, Joshi U, Kadel RW, Kajfasz E, Kamon T, Kaneko T, Kardelis DA, Kasha H, Kato Y, Keeble L, Kennedy RD, Kephart R, Kesten P, Kestenbaum D, Keup RM, Keutelian H, Keyvan F, Kim DH, Kim HS, Kim SB, Kim SH, Kim YK, Kirsch L, Koehn P, Kondo K, Konigsberg J, Kopp S, Kordas K, Koska W, Kovacs E, Kowald W, Krasberg M, Kroll J, Kruse M, Kuhlmann SE, Kuns E, Laasanen AT, Labanca N, Lammel S, Lamoureux JI, LeCompte T, Leone S, Lewis JD, Limon P, Lindgren M, Liss TM, Lockyer N, Loomis C, Long O, Loreti M, Low EH, Lu J, Lucchesi D, Luchini CB, Lukens P, Lys J, Maas P, Maeshima K, Maghakian A, Maksimovic P, Mangano M, Mansour J, Mariotti M, Marriner JP, Martin A, Matthews JAJ, Mattingly R, McIntyre P, Melese P, Menzione A, Meschi E, Michail G, Mikamo S, Miller M, Miller R, Mimashi T, Miscetti S, Mishina M, Mitsushio H, Miyashita S, Morita Y, Moulding S, Mueller J, Mukherjee A, Muller T, Musgrave P, Nakae LF, Nakano I, Nelson C, Neuberger D, Newman-Holmes C, Nodulman L, Ogawa S, Oh SH, Ohl KE, Oishi R, Okusawa T, Pagliarone C, Paoletti R, Papadimitriou V, Pappas SP, Park S, Patrick J, Pauletta G, Paulini M, Pescara L, Peters MD, Phillips TJ, Piacentino G, Pillai M, Plunkett R, Pondrom L, Produit N, Proudfoot J, Ptohos F, Punzi G, Ragan K, Rimondi F, Ristori L, Roach-Bellino M, Robertson WJ, Rodrigo T, Romano J, Rosenson L, Sakumoto WK, Saltzberg D, Sansoni A, Scarpine V, Schindler A, Schlabach P, Schmidt EE, Schmidt MP, Schneider O, Sciacca GF, Scribano A, Segler S, Seidel S, Seiya Y, Sganos G, Sgolacchia A, Shapiro M, Shaw NM, Shen Q, Shepard PF, Shimojima M, Shochet M, Siegrist J, Sill A, Sinervo P, Singh P, Skarha J, Sliwa K, Smith DA, Snider FD, Song L, Song T, Spalding J, Spiegel L, Sphicas P, Stanco L, Steele J, Stefanini A, Strahl K, Strait J, Stuart D, Sullivan G, Sumorok K, Swartz RL, Takahashi T, Takikawa K, Tartarelli F, Taylor W, Teng PK, Teramoto Y, Tether S, Theriot D, Thomas J, Thomas TL, Thun R, Timko M, Tipton P, Titov A, Tkaczyk S, Tollefson K, Tollestrup A, Tonnison J, de Troconiz JF, Tseng J, Turcotte M, Turini N, Uemura N, Ukegawa F, Unal G, van den Brink SC, Vejcik S, Vidal R, Vondracek M, Vucinic D, Wagner RG, Wagner RL, Wainer N, Walker RC, Wang C, Wang CH, Wang G, Wang J, Wang MJ, Wang QF, Warburton A, Watts G, Watts T, Webb R, Wei C, Wendt C, Wenzel H, Wester WC, Westhusing T, Wicklund AB, Wicklund E, Wilkinson R, Williams HH, Wilson P, Winer BL, Wolinski J, Wu DY, Wu X, Wyss J, Yagil A, Yao W, Yasuoka K, Ye Y, Yeh GP, Yeh P, Yin M, Yoh J, Yosef C, Yoshida T, Yovanovitch D, Yu I, Yun JC, Zanetti A, Zetti F, Zhang L, Zhang S, Zhang W, Zucchelli S. Measurement of the associatedγ+μ±production cross section inpp¯collisions ats=1.8TeV. Int J Clin Exp Med 1999. [DOI: 10.1103/physrevd.60.092003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
105
|
Montanelli A, Zulberti M, Mariotti M, Bontempi F, Caimi L. A pseudo-proteinuria? Clin Nephrol 1999; 52:190-1. [PMID: 10499317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
|
106
|
Lefrère JJ, Férec C, Roudot-Thoraval F, Loiseau P, Cantaloube JF, Biagini P, Mariotti M, LeGac G, Mercier B. GBV-C/hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. J Med Virol 1999; 59:32-7. [PMID: 10440805 DOI: 10.1002/(sici)1096-9071(199909)59:1<32::aid-jmv6>3.0.co;2-o] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The aim of this study was to establish the mean plasma GBV-C/hepatitis G virus (HGV) RNA load in groups of GBV-C/HGV-infected individuals with varied immune status and to determine the most frequent patterns of evolution of the plasma GBV-C/HGV RNA load over time during the natural history of infection. The mean plasma GBV-C/HGV RNA load observed was, from the lowest to the highest: 5.21 log in immunodepressed multiply-transfused patients, 6.45 log in HIV-positive individuals, 6.66 log in immunocompetent multiply-transfused patients, and 6.71 log in blood donors. The difference was significant between the four groups (P < 0.0001). The most frequent pattern of evolution of the plasma GBV-C/HGV RNA load was as follows: after the primary GBV-C/HGV infection, the viral load was elevated from the onset; then, a high, persistent and relatively steady viral RNA level was the rule; and when it occurred, the loss of viremia was not preceded by a decrease before recovery from GBV-C/HGV infection.
Collapse
|
107
|
Corada M, Mariotti M, Thurston G, Smith K, Kunkel R, Brockhaus M, Lampugnani MG, Martin-Padura I, Stoppacciaro A, Ruco L, McDonald DM, Ward PA, Dejana E. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A 1999; 96:9815-20. [PMID: 10449777 PMCID: PMC22293 DOI: 10.1073/pnas.96.17.9815] [Citation(s) in RCA: 514] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
In the present paper, we characterize an antibody, mAb BV13, directed to mouse vascular endothelial (VE)-cadherin, a major adhesive protein of interendothelial adherens junctions. When added to cultured endothelial cells, BV13 induces a redistribution of VE-cadherin from intercellular junctions. VE-cadherin redistribution did not change the localization of platelet endothelial cell adhesion molecule or tight junction markers such as zonula occludens 1, cingulin, and junctional adhesion molecule. Intravenous administration of mAb BV13 induced a concentration- and time-dependent increase in vascular permeability in heart and lungs. By electron microscopy, interstitial edema and accumulation of mixed types of inflammatory cells in heart and lungs were observed. Injection of (rhodamine-labeled) Ricinus communis I lectin showed focal spots of exposed basement membrane in the alveolar capillaries and in some larger pulmonary vessels. These data indicate that VE-cadherin is required for vascular integrity and normal organ functions.
Collapse
|
108
|
Lefrère JJ, Mariotti M, Morand-Joubert L, Thauvin M, Roudot-Thoraval F. Plasma human immunodeficiency virus RNA below 40 Copies/mL is rare in untreated persons even in the first years of infection. J Infect Dis 1999; 180:526-9. [PMID: 10395875 DOI: 10.1086/314906] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
To clarify the frequency and prognostic significance of a plasma human immunodeficiency virus (HIV) RNA load below the detection threshold during the natural history of infection, an ultrasensitive assay was used to identify persons with low virus loads in a cohort of 111 untreated subjects with a known date of seroconversion. Six persons had HIV RNA loads <40 viral copies (VC)/mL during the first years of HIV infection. The probability of meeting the criteria for long-term nonprogression was higher in these subjects (P=.043). However, a virus load <40 VC/mL was rare during the natural history of infection, even during the first years of symptomless HIV carriage. Such data confirm the general trend of disease progression in the entire population of HIV carriers.
Collapse
|
109
|
Tommasi S, Carluccio E, Bentivoglio M, Buccolieri M, Mariotti M, Politano M, Corea L. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol 1999; 83:1595-9. [PMID: 10392860 DOI: 10.1016/s0002-9149(99)00162-9] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The prognostic role of C-reactive protein levels in patients with a first acute myocardial infarction, an uncomplicated in-hospital course, and the absence of residual ischemia on a predischarge ergometer test and with an echocardiographic ejection fraction > or = 50% has not been described. C-reactive protein was determined during hospitalization in 64 patients (55 men, mean age 64.6 +/- 10.4 years). The patients were followed up for 13 +/- 4 months and the following cardiac events were recorded: cardiac death, new-onset angina pectoris, and recurrent myocardial infarction. Patients who developed cardiac events during the follow-up period had significantly higher C-reactive protein values than patients without events (3.61 +/- 2.83 vs 1.48 +/- 2.07 mg/dl, p <0.001). The probability of cumulative end points was: 6%, 12%, 31%, and 56% (p = 0.006; RR 3.55; confidence interval 1.56 to 8.04), respectively, in patients stratified by quartiles of C-reactive protein (< 0.45, 0.45 to 0.93, 0.93 to 2.55 and > 2.55 mg/dl). In the Cox regression model, only increased C-reactive protein levels were independently related to the incidence of subsequent cardiac events (chi-square 9.8, p = 0.001). Thus, increased C-reactive protein levels are associated with a worse outcome among patients with a first acute myocardial infarction, an uncomplicated in-hospital course without residual ischemia on the ergometer test, and with normal left ventricular function.
Collapse
|
110
|
Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, Petit JC, Lerable J, Thauvin M, Mariotti M. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J Infect Dis 1999; 179:783-9. [PMID: 10068572 DOI: 10.1086/314671] [Citation(s) in RCA: 112] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
The prevalence of GB virus C (GBV-C) infection is high in human immunodeficiency virus (HIV)-infected persons. However, the long-term consequences of coinfection are unknown. HIV-positive persons with a well-defined duration of infection were screened on the basis of their GBV-C/hepatitis G virus (HGV) RNA status and studied. GBV-C/HGV viremia was observed in 23, who carried the virus over a mean of 7.7 years. All parameters (survival, CDC stage B/C, HIV RNA load, CD4 T cell count) showed significant differences in terms of the cumulative progression rate between persons positive and negative for GBV-C/HGV RNA. When GBV-C/HGV RNA-positive and -unexposed subjects were matched by age, sex, baseline HIV RNA load, and baseline CD4 T cell count, HIV disease progression appeared worse in GBV-C/HGV RNA-negative subjects. The carriage of GBV-C/HGV RNA is associated with a slower progression of HIV disease in coinfected persons.
Collapse
|
111
|
Lefrère JJ, Mariotti M, Thauvin M, Geay D, Larderie P. Detection of viral genomas in serum samples from potential organ donors. Transplantation 1999; 67:639-40. [PMID: 10071043 DOI: 10.1097/00007890-199902270-00028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
112
|
Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, Brossard Y, Parnet-Mathieu F, Mariotti M, Agis F, Rouet G, Lerable J, Lefèvre G, Girot R, Loiseau P. Prevalence of GB virus type C/hepatitis G virus RNA and of anti-E2 in individuals at high or low risk for blood-borne or sexually transmitted viruses: evidence of sexual and parenteral transmission. Transfusion 1999; 39:83-94. [PMID: 9920171 DOI: 10.1046/j.1537-2995.1999.39199116899.x] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
BACKGROUND The first epidemiologic evidence of GB virus type C (GBV-C)/hepatitis G virus (HGV) infection showed a high prevalence of asymptomatic carriers in blood donors and in populations at risk for blood-borne viruses. However, by using only viral RNA polymerase chain reaction, those studies underestimated the true spread of GBV-C/HGV infection. The combined detection of GBV-C/HGV RNA and of anti-E2 (which reflects recovery from infection) is necessary to define accurately the prevalence of GBV-C/HGV. STUDY DESIGN AND METHODS The presence of both anti-E2 and GBV-C/HGV RNA was searched for in 1438 serum samples collected from various groups of individuals at low or high risk for blood-borne or sexually transmitted viruses (blood donors, organ donors, unselected pregnant women, immunocompetent or immunodepressed multiply transfused patients, HIV-positive or HIV-negative homosexual men, intravenous drug addicts). RESULTS The presence of GBV-C/HGV RNA and/or anti-E2 (exposure to GBV-C/HGV) was frequent in populations at risk for blood-borne or sexually transmitted viruses. GBV-C/HGV appeared also to be sexually transmitted, with transmission from male to female more efficient than vice versa. A particularly elevated level of exposure to GBV-C/HGV was observed in homosexual men. In immunocompetent individuals, the prevalence of anti-E2 was about twice that of GBV-C/HGV RNA, which suggests the frequency of recovery from GBV-C/HGV infection. Most of the GBV-C/HGV RNA-positive individuals had no biochemical evidence of liver damage. CONCLUSIONS GBV-C/HGV is frequent in populations at risk for blood-borne or sexually transmitted viruses. GBV-C/HGV is not a hepatitis virus, and it seems appropriate to rename it.
Collapse
|
113
|
Dragoni I, Mariotti M, Consalez GG, Soria MR, Maier JA. EDF-1, a novel gene product down-regulated in human endothelial cell differentiation. J Biol Chem 1998; 273:31119-24. [PMID: 9813014 DOI: 10.1074/jbc.273.47.31119] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Endothelial cell differentiation is a crucial step in angiogenesis. Here we report the identification of EDF-1, a novel gene product that is down-regulated when endothelial cells are induced to differentiate in vitro. The cDNA encoding EDF-1 was isolated by RNA fingerprinting from human endothelial cells exposed to human immunodeficiency virus type 1 Tat, a viral protein known to be angiogenic. The deduced amino acid sequence of EDF-1 encodes a basic intracellular protein of 148 amino acids that is homologous to MBF1 (multiprotein-bridging factor 1) of the silkworm Bombyx mori and to H7, which is implicated in the early developmental events of Dictyostelium discoideum. Interestingly, human immunodeficiency virus type 1 Tat, which affects endothelial functions, and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate and culture on fibrin gels, which promote endothelial differentiation in vitro, all down-regulate EDF-1 expression both at the RNA and protein levels. In addition, the inhibition of EDF-1 translation by an antisense anti-EDF-1 construct results in the inhibition of endothelial cell growth and in the transition from a nonpolar cobblestone phenotype to a polar fibroblast-like phenotype. These data suggest that EDF-1 may play a role in the regulation of human endothelial cell differentiation.
Collapse
|
114
|
Lefrère JJ, Coste J, Defer C, Mercier B, Férec C, Loiseau P, Portelette E, Mariotti M, Lerable J, Rouger P, Pawlotsky JM. Screening blood donations for viral genomes: multicenter study of real-time simulation using pooled samples on the model of hepatitis C virus RNA detection. Transfusion 1998; 38:915-23. [PMID: 9767741 DOI: 10.1046/j.1537-2995.1998.381098440855.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND The systematic screening for several blood-borne viral genomes in blood donations is a complementary safety measure planned or discussed by the national authorities of several countries. STUDY DESIGN AND METHODS To appreciate the feasibility of such screening using pooled samples, a multicenter study of real-time simulation has been performed on the model of hepatitis C virus (HCV) infection. Four blood transfusion center laboratories and two research and diagnosis laboratories simultaneously screened, by several HCV RNA polymerase chain reaction assays, a panel of plasma sample pools of different sizes (500, 100, and 10 samples), collected from HCV-infected or HCV-uninfected blood donors. One viremic plasma was introduced in each pool. HCV RNA was detected by in-house polymerase chain reaction procedures or by standardized manual or semi-automated polymerase chain reaction assays. RESULTS The results indicate the feasibility of sample pooling, which renders the screening for viral genomes by molecular biology techniques applicable in the short term and the importance of the experience of laboratory personnel in the use of molecular biology tools. CONCLUSION The improvement of standardized assays needs to be continued, and training of laboratory staff members appears to be a crucial step before systematic screening of blood donations for viral genomes by molecular biology techniques can occur.
Collapse
|
115
|
Abe F, Akimoto H, Akopian A, Albrow MG, Amadon A, Amendolia SR, Amidei D, Antos J, Aota S, Apollinari G, Arisawa T, Asakawa T, Ashmanskas W, Atac M, Azzi-Bacchetta P, Bacchetta N, Bagdasarov S, Bailey MW, de Barbaro P, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barone M, Bauer G, Baumann T, Bedeschi F, Behrends S, Belforte S, Bellettini G, Bellinger J, Benjamin D, Bensinger J, Beretvas A, Berge JP, Berryhill J, Bertolucci S, Bettelli S, Bevensee B, Bhatti A, Biery K, Bigongiari C, Binkley M, Bisello D, Blair RE, Blocker C, Blusk S, Bodek A, Bokhari W, Bolla G, Bonushkin Y, Bortoletto D, Boudreau J, Breccia L, Bromberg C, Bruner N, Brunetti R, Buckley-Geer E, Budd HS, Burkett K, Busetto G, Byon-Wagner A, Byrum KL, Campbell M, Caner A, Carithers W, Carlsmith D, Cassada J, Castro A, Cauz D, Cerri A, Chang PS, Chang PT, Chao HY, Chapman J, Cheng MT, Chertok M, Chiarelli G, Chiou CN, Chlebana F, Christofek L, Chu ML, Cihangir S, Clark AG, Cobal M, Cocca E, Contreras M, Conway J, Cooper J, Cordelli M, Costanzo D, Couyoumtzelis C, Cronin-Hennessy D, Culbertson R, Dagenhart D, Daniels T, DeJongh F, Dell’Agnello S, Dell’Orso M, Demina R, Demortier L, Deninno M, Derwent PF, Devlin T, Dittmann JR, Donati S, Done J, Dorigo T, Eddy N, Einsweiler K, Elias JE, Ely R, Engels E, Erdmann W, Errede D, Errede S, Fan Q, Feild RG, Feng Z, Ferretti C, Fiori I, Flaugher B, Foster GW, Franklin M, Freeman J, Friedman J, Frisch H, Fukui Y, Gadomski S, Galeotti S, Gallinaro M, Ganel O, Garcia-Sciveres M, Garfinkel AF, Gay C, Geer S, Gerdes DW, Giannetti P, Giokaris N, Giromini P, Giusti G, Gold M, Gordon A, Goshaw AT, Gotra Y, Goulianos K, Grassmann H, Groer L, Grosso-Pilcher C, Guillian G, Guimaraes da Costa J, Guo RS, Haber C, Hafen E, Hahn SR, Hamilton R, Handa T, Handler R, Happacher F, Hara K, Hardman AD, Harris RM, Hartmann F, Hauser J, Hayashi E, Heinrich J, Hao W, Hinrichsen B, Hoffman KD, Hohlmann M, Holck C, Hollebeek R, Holloway L, Huang Z, Huffman BT, Hughes R, Huston J, Huth J, Ikeda H, Incagli M, Incandela J, Introzzi G, Iwai J, Iwata Y, James E, Jensen H, Joshi U, Kajfasz E, Kambara H, Kamon T, Kaneko T, Karr K, Kasha H, Kato Y, Keaffaber TA, Kelley K, Kennedy RD, Kephart R, Kestenbaum D, Khazins D, Kikuchi T, Kim BJ, Kim HS, Kim SH, Kim YK, Kirsch L, Klimenko S, Knoblauch D, Koehn P, Köngeter A, Kondo K, Konigsberg J, Kordas K, Korytov A, Kovacs E, Kowald W, Kroll J, Kruse M, Kuhlmann SE, Kuns E, Kurino K, Kuwabara T, Laasanen AT, Nakano I, Lami S, Lammel S, Lamoureux JI, Lancaster M, Lanzoni M, Latino G, LeCompte T, Leone S, Lewis JD, Limon P, Lindgren M, Liss TM, Liu JB, Liu YC, Lockyer N, Long O, Loomis C, Loreti M, Lucchesi D, Lukens P, Lusin S, Lys J, Maeshima K, Maksimovic P, Mangano M, Mariotti M, Marriner JP, Martin A, Matthews JAJ, Mazzanti P, McIntyre P, Melese P, Menguzzato M, Menzione A, Meschi E, Metzler S, Miao C, Miao T, Michail G, Miller R, Minato H, Miscetti S, Mishina M, Miyashita S, Moggi N, Moore E, Morita Y, Mukherjee A, Muller T, Murat P, Murgia S, Nakada H, Nakano I, Nelson C, Neuberger D, Newman-Holmes C, Ngan CYP, Nodulman L, Nomerotski A, Oh SH, Ohmoto T, Ohsugi T, Oishi R, Okabe M, Okusawa T, Olsen J, Pagliarone C, Paoletti R, Papadimitriou V, Pappas SP, Parashar N, Parri A, Patrick J, Pauletta G, Paulini M, Perazzo A, Pescara L, Peters MD, Phillips TJ, Piacentino G, Pillai M, Pitts KT, Plunkett R, Pompos A, Pondrom L, Proudfoot J, Ptohos F, Punzi G, Ragan K, Reher D, Reischl M, Ribon A, Rimondi F, Ristori L, Robertson WJ, Rodrigo T, Rolli S, Rosenson L, Roser R, Saab T, Sakumoto WK, Saltzberg D, Sansoni A, Santi L, Sato H, Schlabach P, Schmidt EE, Schmidt MP, Scott A, Scribano A, Segler S, Seidel S, Seiya Y, Semeria F, Shah T, Shapiro MD, Shaw NM, Shepard PF, Shibayama T, Shimojima M, Shochet M, Siegrist J, Sill A, Sinervo P, Singh P, Sliwa K, Smith C, Snider FD, Spalding J, Speer T, Sphicas P, Spinella F, Spiropulu M, Spiegel L, Stanco L, Steele J, Stefanini A, Ströhmer R, Strologas J, Strumia F, Stuart D, Sumorok K, Suzuki J, Suzuki T, Takahashi T, Takano T, Takashima R, Takikawa K, Tanaka M, Tannenbaum B, Tartarelli F, Taylor W, Tecchio M, Teng PK, Teramoto Y, Terashi K, Tether S, Theriot D, Thomas TL, Thurman-Keup R, Timko M, Tipton P, Titov A, Tkaczyk S, Toback D, Tollefson K, Tollestrup A, Toyoda H, Trischuk W, de Troconiz JF, Truitt S, Tseng J, Turini N, Uchida T, Ukegawa F, Valls J, van den Brink SC, Vejcik S, Velev G, Vidal R, Vilar R, Vucinic D, Wagner RG, Wagner RL, Wahl J, Wallace NB, Walsh AM, Wang C, Wang CH, Wang MJ, Warburton A, Watanabe T, Watts T, Webb R, Wei C, Wenzel H, Wester WC, Wicklund AB, Wicklund E, Wilkinson R, Williams HH, Wilson P, Winer BL, Winn D, Wolinski D, Wolinski J, Worm S, Wu X, Wyss J, Yagil A, Yao W, Yasuoka K, Yeh GP, Yeh P, Yoh J, Yosef C, Yoshida T, Yu I, Zanetti A, Zetti F, Zucchelli S. Search for the rare decayW±→Ds±γinpp¯collisions ats=1.8TeV. Int J Clin Exp Med 1998. [DOI: 10.1103/physrevd.58.091101] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
116
|
Abe F, Akimoto H, Akopian A, Albrow MG, Amadon A, Amendolia SR, Amidei D, Antos J, Aota S, Apollinari G, Arisawa T, Asakawa T, Ashmanskas W, Atac M, Azzi-Bacchetta P, Bacchetta N, Bagdasarov S, Bailey MW, de Barbaro P, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barone M, Bauer G, Baumann T, Bedeschi F, Behrends S, Belforte S, Bellettini G, Bellinger J, Benjamin D, Bensinger J, Beretvas A, Berge JP, Berryhill J, Bertolucci S, Bettelli S, Bevensee B, Bhatti A, Biery K, Bigongiari C, Binkley M, Bisello D, Blair RE, Blocker C, Blusk S, Bodek A, Bokhari W, Bolla G, Bonushkin Y, Bortoletto D, Boudreau J, Breccia L, Bromberg C, Bruner N, Brunetti R, Buckley-Geer E, Budd HS, Burkett K, Busetto G, Byon-Wagner A, Byrum KL, Campbell M, Caner A, Carithers W, Carlsmith D, Cassada J, Castro A, Cauz D, Cerri A, Chang PS, Chang PT, Chao HY, Chapman J, Cheng MT, Chertok M, Chiarelli G, Chiou CN, Chlebana F, Christofek L, Chu ML, Cihangir S, Clark AG, Cobal M, Cocca E, Contreras M, Conway J, Cooper J, Cordelli M, Costanzo D, Couyoumtzelis C, Cronin-Hennessy D, Culbertson R, Dagenhart D, Daniels T, DeJongh F, Dell’Agnello S, Dell’Orso M, Demina R, Demortier L, Deninno M, Derwent PF, Devlin T, Dittmann JR, Donati S, Done J, Dorigo T, Eddy N, Einsweiler K, Elias JE, Ely R, Engles E, Erdmann W, Errede D, Errede S, Fan Q, Feild RG, Feng Z, Ferretti C, Fiori I, Flaugher B, Foster GW, Franklin M, Freeman J, Friedman J, Frisch H, Fukui Y, Gadomski S, Galeotti S, Gallinaro M, Ganel O, Garcia-Sciveres M, Garfinkel AF, Gay C, Geer S, Gerdes DW, Giannetti P, Giokaris N, Giromini P, Giusti G, Gold M, Gordon A, Goshaw AT, Gotra Y, Goulianos K, Grassmann H, Groer L, Grosso-Pilcher C, Guillian G, Guimaraes da Costa J, Guo RS, Haber C, Hafen E, Hahn SR, Hamilton R, Handa T, Handler R, Happacher F, Hara K, Hardman AD, Harris RM, Hartmann F, Hauser J, Hayashi E, Heinrich J, Hao W, Hinrichsen B, Hoffman KD, Hohlmann M, Holck C, Hollebeek R, Holloway L, Huang Z, Huffman BT, Hughes R, Huston J, Huth J, Ikeda H, Incagli M, Incandela J, Introzzi G, Iwai J, Iwata Y, James E, Jensen H, Joshi U, Kadel RW, Kajfasz E, Kambara H, Kamon T, Kaneko T, Karr K, Kasha H, Kato Y, Keaffaber TA, Kelley K, Kennedy RD, Kephart R, Kestenbaum D, Khazins D, Kikuchi T, Kim BJ, Kim HS, Kim SH, Kim YK, Kirsch L, Klimenko S, Knoblauch D, Koehn P, Köngeter A, Kondo K, Konigsberg J, Kordas K, Korytov A, Kovacs E, Kowald W, Kroll J, Kruse M, Kuhlmann SE, Kuns E, Kurino K, Kuwabara T, Laasanen AT, Nakano I, Lami S, Lammel S, Lamoureux JI, Lancaster M, Lanzoni M, Latino G, LeCompte T, Leone S, Lewis JD, Limon P, Lindgren M, Liss TM, Liu JB, Liu YC, Lockyer N, Long O, Loomis C, Loreti M, Lucchesi D, Lukens P, Lusin S, Lys J, Maeshima K, Maksimovic P, Mangano M, Mariotti M, Marriner JP, Martin A, Matthews JAJ, Mazzanti P, McIntyre P, Melese P, Menguzzato M, Menzione A, Meschi E, Metzler S, Miao C, Miao T, Michail G, Miller R, Minato H, Miscetti S, Mishina M, Miyashita S, Moggi N, Moore E, Morita Y, Mukherjee A, Muller T, Murat P, Murgia S, Nakada H, Nakano I, Nelson C, Neuberger D, Newman-Holmes C, Ngan CYP, Nodulman L, Nomerotski A, Oh SH, Ohmoto T, Ohsugi T, Oishi R, Okabe M, Okusawa T, Olsen J, Pagliarone C, Paoletti R, Papadimitriou V, Pappas SP, Parashar N, Parri A, Patrick J, Pauletta G, Paulini M, Perazzo A, Pescara L, Peters MD, Phillips TJ, Piacentino G, Pillai M, Pitts KT, Plunkett R, Pompos A, Pondrom L, Proudfoot J, Ptohos F, Punzi G, Ragan K, Reher D, Reischl M, Ribon A, Rimondi F, Ristori L, Robertson WJ, Rodrigo T, Rolli S, Rosenson L, Roser R, Saab T, Sakumoto WK, Saltzberg D, Sansoni A, Santi L, Sato H, Schlabach P, Schmidt EE, Schmidt MP, Scott A, Scribano A, Segler S, Seidel S, Seiya Y, Semeria F, Shah T, Shapiro MD, Shaw NM, Shepard PF, Shibayama T, Shimojima M, Shochet M, Siegrist J, Sill A, Sinervo P, Singh P, Sliwa K, Smith C, Snider FD, Spalding J, Speer T, Sphicas P, Spinella F, Spiropulu M, Spiegel L, Stanco L, Steele J, Stefanini A, Ströhmer R, Strologas J, Strumia F, Stuart D, Sumorok K, Suzuki J, Suzuki T, Takahashi T, Takano T, Takashima R, Takikawa K, Tanaka M, Tannenbaum B, Tartarelli F, Taylor W, Tecchio M, Teng PK, Teramoto Y, Terashi K, Tether S, Theriot D, Thomas TL, Thurman-Keup R, Timko M, Tipton P, Titov A, Tkaczyk S, Toback D, Tollefson K, Tollestrup A, Toyoda H, Trischuk W, de Troconiz JF, Truitt S, Tseng J, Turini N, Uchida T, Ukegawa F, Valls J, van den Brink SC, Vejcik S, Velev G, Vidal R, Vilar R, Vucinic D, Wagner RG, Wagner RL, Wahl J, Wallace NB, Walsh AM, Wang C, Wang CH, Wang MJ, Warburton A, Watanabe T, Watts T, Webb R, Wei C, Wenzel H, Wester WC, Wicklund AB, Wicklund E, Wilkinson R, Williams HH, Wilson P, Winer BL, Winn D, Wolinski D, Wolinski J, Worm S, Wu X, Wyss J, Yagil A, Yao W, Yasuoka K, Yeh GP, Yeh P, Yoh J, Yosef C, Yoshida T, Yu I, Zanetti A, Zetti F, Zucchelli S. Search for the rare decayW±→π±+γin proton-antiproton collisions ats=1.8 TeV. Int J Clin Exp Med 1998. [DOI: 10.1103/physrevd.58.031101] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
117
|
Gritti I, Mariotti M, Mancia M. GABAergic and cholinergic basal forebrain and preoptic-anterior hypothalamic projections to the mediodorsal nucleus of the thalamus in the cat. Neuroscience 1998; 85:149-78. [PMID: 9607710 DOI: 10.1016/s0306-4522(97)00573-3] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The present study examined projections of GABAergic and cholinergic neurons from the basal forebrain and preoptic-anterior hypothalamus to the "intermediate" part of the mediodorsal nucleus of the thalamus. Retrograde transport from this region of the mediodorsal nucleus was investigated using horseradish peroxidase-conjugated wheatgerm agglutinin in combination with peroxidase-antiperoxidase immunohistochemical staining for glutamic acid decarboxylase and choline acetyltransferase. A relatively large number of retrogradely-labelled glutamic acid decarboxylase-positive neurons are located in the basal forebrain, amounting to more than 7% of the total population of glutamic acid decarboxylase-positive cells in this region. Moreover, retrogradely-labelled choline acetyltransferase-positive cells are interspersed among glutamic acid decarboxylase-positive neurons, accounting for about 6% of the total choline acetyltransferase-positive cell population in the basal forebrain. The glutamic acid decarboxylase-positive and choline acetyltransferase-positive retrogradely-labelled neurons are distributed throughout several regions of the basal forebrain, including the medial septum, the diagonal band of Broca, the magnocellular preoptic nucleus, the substantia innominata pars anterior, the substantia innominata pars posterior, and the globus pallidus where only a few retrogradely-labelled neurons were seen. The choline acetyltransferase-positive mediodorsal-projecting neurons are morphologically different from the choline acetyltransferase-positive neurons in the basal forebrain, suggesting that those projecting to the mediodorsal nucleus are a small proportion of the cholinergic neuronal population in the basal forebrain. In the preoptic-anterior hypothalamus, many retrogradely-labelled glutamic acid decarboxylase-positive cells were found, amounting to more than 7% of the total population of glutamic acid decarboxylase-positive cells in this region. These retrogradely-labelled glutamic acid decarboxylase-positive neurons are distributed throughout the preoptic-anterior hypothalamus in a continuous line with those in the basal forebrain, including the lateral preoptic area, the medial preoptic area, the bed nucleus of the stria terminalis, and the anterior and dorsal hypothalamic areas. The highest percentage of mediodorsal-projecting GABAergic neurons is in the anterior lateral hypothalamus where more than 25% of the total population of glutamic acid decarboxylase-positive cells project to the mediodorsal nucleus of the thalamus. Overall, of the large population of retrogradely-labelled neurons in the basal forebrain and preoptic-anterior hypothalamus, a significant proportion are glutamic acid decarboxylase-positive neurons (> 60% in the basal forebrain and > 30% in the preoptic-anterior hypothalamus), while the choline acetyltransferase-positive neurons amount to a smaller percentage of the neurons projecting to the mediodorsal nucleus (< 13% in the basal forebrain and < 2% in the preoptic-anterior hypothalamus). These results provide anatomical evidence of direct GABAergic projections from the basal forebrain and preoptic-anterior hypothalamic regions to the "intermediate" part of the mediodorsal nucleus in the cat. This GABAergic projection field could be the direct pathway by which the basal forebrain directly modulates thalamic excitability and may also be involved in mechanisms modulating electroencephalographic synchronization and sleep through the "intermediate" mediodorsal nucleus.
Collapse
|
118
|
Lefrère JJ, Roudot-Thoraval F, Mariotti M, Thauvin M, Lerable J, Salpétrier J, Morand-Joubert L. The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. J Infect Dis 1998; 177:1541-8. [PMID: 9607831 DOI: 10.1086/515308] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
A cohort of 103 human immunodeficiency virus type 1 (HIV-1)-infected persons with well-defined dates of seroconversion were studied to determine whether baseline plasma HIV RNA loads 6-12 months after seroconversion have prognostic value. Baseline plasma virus loads had predictive value for the disease-free survival rate and for the survival rate. The level of baseline HIV RNA also had a strong negative predictive value for the CD4+ T cell count during the fifth year of infection: A baseline load >5 log was predictive of a CD4+ T cell count <500/mm3 5 years after infection. Baseline HIV RNA load was a CD4+ T cell-independent predictor of progression to death. The major finding was that the disease outcome for HIV-1-infected persons is already determined during the first year of infection.
Collapse
|
119
|
Stingeni L, Mariotti M, Lisi P. Airborne allergic contact dermatitis from iroko (Chlorophora excelsa). Contact Dermatitis 1998; 38:287. [PMID: 9667453 DOI: 10.1111/j.1600-0536.1998.tb05750.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
120
|
Tateo F, Mariotti M, Bononi M. Essential Oil Composition and Enantiomeric Distribution of Some Monoterpenoid Components ofCoridothymus capitatus(L.) Rchb. Grown on the Island of Kos (Greece). JOURNAL OF ESSENTIAL OIL RESEARCH 1998. [DOI: 10.1080/10412905.1998.9700895] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
121
|
Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, Brassard Y, Parnet-Mathieu F, Mariotti M, Agis F, Rouet F, Lerable J, Lefèvre G, Girot R, Loiseau P. P9-5 Prévalence de l'ARN du virus de l'hépatite G (VHG) et de l'anticorps anti-E2 dans différentes populations de sujets à risque de contamination sanguine et/ou sexuelle. Transfus Clin Biol 1998. [DOI: 10.1016/s1246-7820(98)80155-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
122
|
Abe F, Albrow MG, Amendolia SR, Amidei D, Antos J, Anway-Wiese C, Apollinari G, Areti H, Atac M, Auchincloss P, Azfar F, Azzi P, Bacchetta N, Badgett W, Bailey MW, Bao J, de Barbaro P, Barbaro-Galtieri A, Barnes VE, Barnett BA, Bartalini P, Bauer G, Baumann T, Bedeschi F, Behrends S, Belforte S, Bellettini G, Bellinger J, Benjamin D, Benlloch J, Bensinger J, Benton D, Beretvas A, Berge JP, Bertolucci S, Bhatti A, Biery K, Binkley M, Bird F, Bisello D, Blair RE, Blocker C, Bodek A, Bokhari W, Bolognesi V, Bortoletto D, Boswell C, Boulos T, Brandenburg G, Bromberg C, Buckley-Geer E, Budd HS, Burkett K, Busetto G, Byon-Wagner A, Byrum KL, Cammerata J, Campagnari C, Campbell M, Caner A, Carithers W, Carlsmith D, Castro A, Cen Y, Cervelli F, Chao HY, Chapman J, Cheng MT, Chiarelli G, Chikamatsu T, Chiou CN, Christofek L, Cihangir S, Clark AG, Cobal M, Contreras M, Conway J, Cooper J, Cordelli M, Couyoumtzelis C, Crane D, Cunningham JD, Daniels T, DeJongh F, Delchamps S, Dell’Agnello S, Dell’Orso M, Demortier L, Denby B, Deninno M, Derwent PF, Devlin T, Dickson M, Dittmann JR, Donati S, Drucker RB, Dunn A, Einsweiler K, Elias JE, Ely R, Engels E, Eno S, Errede D, Errede S, Fan Q, Farhat B, Fiori I, Flaugher B, Foster GW, Franklin M, Frautschi M, Freeman J, Friedman J, Frisch H, Fry A, Fuess TA, Fukui Y, Funaki S, Gagliardi G, Galeotti S, Gallinaro M, Garfinkel AF, Geer S, Gerdes DW, Giannetti P, Giokaris N, Giromini P, Gladney L, Glenzinski D, Gold M, Gonzalez J, Gordon A, Goshaw AT, Goulianos K, Grassmann H, Grewal A, Groer L, Grosso-Pilcher C, Haber C, Hahn SR, Hamilton R, Handler R, Hans RM, Hara K, Harral B, Harris RM, Hauger SA, Hauser J, Hawk C, Heinrich J, Cronin-Hennessy D, Hollebeek R, Holloway L, Hölscher A, Hong S, Houk G, Hu P, Huffman BT, Hughes R, Hurst P, Huston J, Huth J, Hylen J, Incagli M, Incandela J, Iso H, Jensen H, Jessop CP, Joshi U, Kadel RW, Kajfasz E, Kamon T, Kaneko T, Kardelis DA, Kasha H, Kato Y, Keeble L, Kennedy RD, Kephart R, Kesten P, Kestenbaum D, Keup RM, Keutelian H, Keyvan F, Kim DH, Kim HS, Kim SB, Kim SH, Kim YK, Kirsch L, Koehn P, Kondo K, Konigsberg J, Kopp S, Kordas K, Koska W, Kovacs E, Kowald W, Krasberg M, Kroll J, Kruse M, Kuhlmann SE, Kuns E, Laasanen AT, Labanca N, Lammel S, Lamoureux JI, LeCompte T, Leone S, Lewis JD, Limon P, Lindgren M, Liss TM, Lockyer N, Loomis C, Long O, Loreti M, Low EH, Lu J, Lucchesi D, Luchini CB, Lukens P, Lys J, Maas P, Maeshima K, Maghakian A, Maksimovic P, Mangano M, Mansour J, Mariotti M, Marriner JP, Martin A, Matthews JAJ, Mattingly R, McIntyre P, Melese P, Menzione A, Meschi E, Michail G, Mikamo S, Miller M, Miller R, Mimashi T, Miscetti S, Mishina M, Mitsushio H, Miyashita S, Morita Y, Moulding S, Mueller J, Mukherjee A, Muller T, Musgrave P, Nakae LF, Nakano I, Nelson C, Neuberger D, Newman-Holmes C, Nodulman L, Ogawa S, Oh SH, Ohl KE, Oishi R, Okusawa T, Pagliarone C, Paoletti R, Papadimitriou V, Pappas SP, Park S, Patrick J, Pauletta G, Paulini M, Pescara L, Peters MD, Phillips TJ, Piacentino G, Pillai M, Plunkett R, Pondrom L, Produit N, Proudfoot J, Ptohos F, Punzi G, Ragan K, Rimondi F, Ristori L, Roach-Bellino M, Robertson WJ, Rodrigo T, Romano J, Rosenson L, Sakumoto WK, Saltzberg D, Sansoni A, Scarpine V, Schindler A, Schlabach P, Schmidt EE, Schmidt MP, Schneider O, Sciacca GF, Scribano A, Segler S, Seidel S, Seiya Y, Sganos G, Sgolacchia A, Shapiro M, Shaw NM, Shen Q, Shepard PF, Shimojima M, Shochet M, Siegrist J, Sill A, Sinervo P, Singh P, Skarha J, Sliwa K, Smith DA, Snider FD, Song L, Song T, Spalding J, Spiegel L, Sphicas P, Stanco L, Steele J, Stefanini A, Strahl K, Strait J, Stuart D, Sullivan G, Sumorok K, Swartz RL, Takahashi T, Takikawa K, Tartarelli F, Taylor W, Teng PK, Teramoto Y, Tether S, Theriot D, Thomas J, Thomas TL, Thun R, Timko M, Tipton P, Titov A, Tkaczyk S, Tollefson K, Tollestrup A, Tonnison J, de Troconiz JF, Tseng J, Turcotte M, Turini N, Uemura N, Ukegawa F, Unal G, van den Brink SC, Vejcik S, Vidal R, Vondracek M, Vucinic D, Wagner RG, Wagner RL, Wainer N, Walker RC, Wang C, Wang CH, Wang G, Wang J, Wang MJ, Wang QF, Warburton A, Watts G, Watts T, Webb R, Wei C, Wendt C, Wenzel H, Wester WC, Westhusing T, Wicklund AB, Wicklund E, Wilkinson R, Williams HH, Wilson P, Winer BL, Wolinski J, Wu DY, Wu X, Wyss J, Yagil A, Yao W, Yasuoka K, Ye Y, Yeh GP, Yeh P, Yin M, Yoh J, Yosef C, Yoshida T, Yovanovitch D, Yu I, Yun JC, Zanetti A, Zetti F, Zhang L, Zhang S, Zhang W, Zucchelli S. Jet pseudorapidity distribution in direct photon events inpp¯collisions ats=1.8TeV. Int J Clin Exp Med 1998. [DOI: 10.1103/physrevd.57.1359] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
123
|
Morand-Joubert L, Vittecoq D, Roudot-Thoraval F, Mariotti M, Lefrère F, Heshmati F, Audat F, Lambin P, Barré-Sinoussi F, Lefrère JJ. Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies). Vox Sang 1997; 73:149-54. [PMID: 9358616 DOI: 10.1046/j.1423-0410.1997.7330149.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND AND OBJECTIVES In human immunodeficiency virus (HIV) infections, passive immunotherapy can be carried out through infusions of virus-inactivated plasma from symptomless HIV-infected persons with abundant HIV antibodies. MATERIALS AND METHODS We carried out a prospective, randomized, double-blind, controlled, passive immunotherapy study, which compared two groups. One received plasma rich in HIV antibodies, the other a standard seronegative plasma. RESULTS Measurement of the plasma HIV RNA load showed in both groups a significant decrease in the mean viral copy number at the end of the first month, followed by an increase at the third month. Beyond the third months, a significant decrease in viral load was observed only in the treatment group. A significant difference in favor of the treatment group was observed for plasma viremia by HIV culture. For the cytokines involved in the viral replication and for the immune activation markers such as neopterin and beta 2-microglobulin, the biological analysis in plasma failed to show a significant difference in either group. Clinically, the treatment group benefited by delay in the appearance of the first AIDS-defining event and reduction in the cumulative incidence of such events. CONCLUSION One possible interpretation is that passive immunotherapy affects plasma viral load, but there is no evidence that HIV-specific antibodies are exclusively responsible for the observed effects.
Collapse
|
124
|
Lefrère JJ, Loiseau P, Maury J, Lasserre J, Mariotti M, Ravera N, Lerable J, Lefèvre G, Morand-Joubert L, Girot R. Natural history of GBV-C/hepatitis G virus infection through the follow-up of GBV-C/hepatitis G virus-infected blood donors and recipients studied by RNA polymerase chain reaction and anti-E2 serology. Blood 1997; 90:3776-80. [PMID: 9345065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The aims of this study were to determine the outcome and the natural history of GBV-C/hepatitis G virus (HGV) infection and to establish the frequency of acute or persistent infections in multiply-transfused individuals and blood donors. We used a GBV-C/HGV RNA polymerase chain reaction (PCR) and an assay evidencing antibodies to the envelop protein E2, which is considered a marker for virus clearance. Among 16 PCR-positive recipients, 11 were still positive for GBV-C/HGV RNA at the end of the study period; six of the 16 recipients were GBV-C/HGV infected during the study period and thus had a well-defined date of infection. The 16 patients were shown to carry GBV-C/HGV RNA over a mean period of 4.4 years, for a mean observational period (defined as the follow-up period since the first sample positive for GBV-C/HGV RNA) of 5.3 years. Within the limits of the study period, the patients with a well-defined date of infection were positive for GBV-C/HGV RNA during a mean period of 4.7 years. If defined by the presence of GBV-C/HGV RNA for at least 6 months, the persistent infection rate was 100% in this recipient cohort. Serum anti-E2 antibody was evidenced at least once in five (31.2%) recipients and, except in one case, became detectable after the loss of GBV-C/HGV RNA. Among the 11 blood donors, all were still positive for GBV-C/HGV RNA after a mean follow-up period of 7.7 months. The persistent infection rate was 100% in this donor cohort. Once acquired, the infection to GBV-C/HGV generally tends to persist in immunocompetent patients.
Collapse
|
125
|
Cavallaro U, Mariotti M, Wu ZH, Soria MR, Maier JA. Fibronectin modulates endothelial response to HIV type 1 Tat. AIDS Res Hum Retroviruses 1997; 13:1341-8. [PMID: 9339851 DOI: 10.1089/aid.1997.13.1341] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The normal function of the endothelium is impaired in HIV-1 infection. Disturbances of the local cytokines as well as the release of HIV-1 Tat by infected mononuclear cells play a role in endothelial dysfunction. We studied the effects of Tat on the human endothelial ECV cell line. In this system, Tat inhibited cell proliferation only in the presence of fibronectin as a culture substrate, whereas it did not modulate plasminogen activator activity, cell migration, or synthesis of fibronectin. Because amino acids 49-57 contains a nuclear translocation sequence, we also evaluated the potential intracellular role of Tat in tat-transfected ECV cells. tat transfectants showed inhibition of cell growth, unaffected cell migration and plasminogen activator activity, and a significant induction of the expression of fibronectin.
Collapse
|
126
|
Lefrère JJ, Morand-Joubert L, Mariotti M, Bludau H, Burghoffer B, Petit JC, Roudot-Thoraval F. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 1997; 90:1133-40. [PMID: 9242545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Despite a decade of human immunodeficiency virus (HIV) seropositivity, a few individuals termed as long-term nonprogressors (LTNPs) maintain a stable CD4+ T-cell count for a period of time. The aim of this study was to establish, through the sequential determination of all known predictors of HIV disease, the proportion of such patients having stringent criteria of true long-term nonprogression. Among 249 individuals who were HIV-infected and prospectively followed up over a 10-year period (1985 to 1995), 12 having a CD4+ T-cell count greater than 500/microL (LTNP I group) and 9 having a CD4+ T-cell count less than 500 but stable over time (LTNP II group) after at least 10 years of infection without intervention of antiviral therapy, were studied over the entire follow-up period. The plasma HIV RNA copy number and the serum concentrations of p24 antigen, each anti-HIV antibody, neopterin, beta-2-microglobulin, Immunoglobulin (Ig) G and IgA were determined every 18 months over the study period. Cellular and plasma viremias were cross-sectionaly assayed in all 21 patients. Only two patients had strictly no marker of progression over the follow-up period. They were the only ones who had, over the 10-year period, a viral copy number too low to be detected. The other patients had a viral copy number higher than 400/mL at at least one visit and increasing over the follow-up period, and they evidenced one or more markers of virological or immunological deterioration. Cellular viremia was positive in all patients but two, while plasma viremia was negative in all but one. The population of individuals termed as LTNPs is not virologically and immunologically homogeneous. The majority present biological signs of HIV disease progression. A new pattern of true LTNP can be drawn through stringent criteria based on the whole known predictors. This pattern appears to be rare in HIV-positive population.
Collapse
|
127
|
|
128
|
Loiseau P, Mariotti M, Corbi C, Ravera N, Girot R, Thauvin M, Portelette E, Mariette X, Roudot-Thoraval F, Benbunan M, Lefrère JJ. Prevalence of hepatitis G virus RNA in French blood donors and recipients. Transfusion 1997; 37:645-50. [PMID: 9191827 DOI: 10.1046/j.1537-2995.1997.37697335161.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Recently, cases of chronic hepatitis were linked to the presence of genomic sequences of a newly described RNA virus termed hepatitis G virus (HGV) and belonging to the Flaviviridae family. STUDY DESIGN AND METHODS The presence of HGV RNA was searched for by polymerase chain reaction in a population of blood donors and in patients who had received multiple blood component transfusions and/or intravenous immunoglobulin (IVIG) infusions. RESULTS Twenty-one (4.2%) of 500 donors were positive for HGV RNA as were 21 (10.7%) of 196 nonimmunosuppressed patients who had received multiple transfusions of packed red cells, 4 (8.7%) of 46 common variable immune deficiency (CVID) patients who had received only IVIG, and 22 (24.7%) of 89 bone marrow transplant (BMT) patients who had received IVIG and cellular components. The proportion of HGV-positive individuals was significantly higher in the immunosuppressed recipients (CVID and BMT patients) than in the nonimmunosuppressed patients who were multiply transfused with packed red cells (p < 0.03). The proportion of HGV-positive individuals was significantly higher in the BMT patients who had received IVIG and cellular components than in the CVID patients who had received IVIG only (p < 0.03). Eight (17.0%) of the 47 HGV-positive recipients and 48 (16.9%) of the 284 HGV-negative recipients had a serum alanine aminotransferase level higher than the upper limit of normal (nonsignificant difference). The medical history of HGV-positive donors failed to reveal a particular at-risk event. The large majority of HGV-infected patients had a normal serum alanine aminotransferase level, and the proportion of patients with elevated alanine aminotransferase was the same in HGV-positive and in HGV-negative recipients. CONCLUSION The pathological significance of HGV infection remains unelucidated, and the classification of HGV as a new hepatitis virus was perhaps premature.
Collapse
|
129
|
Lefrère JJ, Guiramand S, Lefrère F, Mariotti M, Aumont P, Lerable J, Petit JC, Girot R, Morand-Joubert L. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 1997; 175:316-22. [PMID: 9203652 DOI: 10.1093/infdis/175.2.316] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Cases of partial seroreversion have been reported in hemodialyzed or immunodepressed patients, but spontaneous clearance of viremia associated with a disappearance of specific antibodies or clearance while receiving therapy has not been precisely documented in immunocompetent hepatitis C virus (HCV)-infected persons. A longitudinal study of markers of HCV infection in a cohort of 178 multitransfused patients followed over an 8-year period was done to establish well-documented cases of partial or full seroreversion. Thirty (16.8%) of 178 patients were HCV-infected; among them, 5 had partial or full seroreversion. Seroreversion to an anti-HCV-negative state is characterized by a quantitative decrease in antibody. A seroreversion may be observed in three circumstances: spontaneously, induced by therapy, and in conjunction with human immunodeficiency virus infection. Long-term follow-up of seroreverters will establish whether they have definitively eradicated HCV from their systems.
Collapse
|
130
|
|
131
|
Lefrere JJ, Mariotti M, Lerable J, Thauvin M, Girot R. Long-term persistence of hepatitis G virus in immunocompetent patients. Lancet 1996; 348:1174-5. [PMID: 8888199 DOI: 10.1016/s0140-6736(05)65313-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
132
|
Maier J, Mariotti M, Comoglio PM, Soria MR. Interleukin 1 induces an autocrine loop hepatocyte growth factor/c-Met in murine Kaposi-like spindle cells. Oncogene 1996; 13:1009-15. [PMID: 8806690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Several cytokines, growth factors and the HIV transactivator Tat were shown to be involved in the pathogenesis of Kaposi's sarcoma. BKV/tat transgenic mice develop Kaposi's sarcoma-like lesions, and spindle-shaped cells (TTB) have been derived from these lesions. Here we show that TTB cells co-express hepatocyte growth factor (HGF) and its receptor, the product of the oncogene c-Met. An autocrine loop HGF/Met sustains spindle cell proliferation in vitro; indeed, an antisense oligomer targeted against HGF markedly inhibited cell growth. Moreover, HGF and Met are overexpressed after exposing TTB cells to the proinflammatory cytokine interleukin 1 (IL-1). We argue that upon exposure to IL-1, an HGF/Met autocrine loop is induced which could explain the appearance of multiple foci of uncontrolled growth. In addition, due to its angiogenic activity, HGF may also sustain the neovascularization typical of Kaposi's sarcoma lesions.
Collapse
|
133
|
Lefrère JJ, Meyohas MC, Mariotti M, Meynard JL, Thauvin M, Frottier J. Detection of human herpesvirus 8 DNA sequences before the appearance of Kaposi's sarcoma in human immunodeficiency virus (HIV)-positive subjects with a known date of HIV seroconversion. J Infect Dis 1996; 174:283-7. [PMID: 8699056 DOI: 10.1093/infdis/174.2.283] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
The presence of human herpesvirus 8 (HHV-8) DNA sequences was sought by polymerase chain reaction (PCR) in peripheral blood mononuclear cells of 4 groups: 6 human immunodeficiency virus (HIV)-infected persons with well-defined dates of seroconversion, during the period between the diagnosis of HIV infection and the appearance of Kaposi's sarcoma (KS); 45 HIV-positive persons with no symptoms of HIV infection; 11 AIDS patients with KS; and 14 AIDS patients without KS. HHV-8 DNA PCR was positive in 3 of the 6 patients during HIV infection preceding the appearance of KS and in all but 1 of 11 AIDS patients with KS. HHV-8 DNA PCR was negative in all but 1 of the 45 HIV-positive persons with no symptoms of infection and in all but 1 AIDS patient without KS. These results indicate that HHV-8 DNA may be detected several years before the occurrence of KS in HIV-infected subjects.
Collapse
|
134
|
Manzato A, Picchioni A, Mastropiero R, Gallotti A, Pepi P, Ferrari R, Mariotti M, Marzollo P. A.104 Role of pulmonary and bronchial circulation in neutrophil-mediated lung damage induced by cardiopulmonary bypass. Br J Anaesth 1996. [DOI: 10.1016/s0007-0912(18)30959-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
135
|
Lefrère JJ, Loiseau P, Martinot-Peignoux M, Mariotti M, Ravera N, Thauvin M, Marcellin P, Janot C. Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France. Transfusion 1996; 36:394-7. [PMID: 8693501 DOI: 10.1046/j.1537-2995.1996.36596282581.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND A recent hepatitis C virus (HCV) outbreak has been suspected of being caused by an infusion of intravenous immune globulin. STUDY DESIGN AND METHODS Three laboratories were mandated by the French regulatory agency to prospectively screen on a national scale those persons having received suspected batches: 233 exposed patients were recalled and tested for HCV antibody and for HCV RNA. RESULTS Nineteen patients (8.1%) were found positive for HCV RNA; 7 of these 19 were positive for the HCV antibody. CONCLUSION The link between HCV infection and intravenous immune globulin was reinforced by the overrepresentation of the 2b genotype (58%), which contrasts with the low prevalence of this genotype in France (1%).
Collapse
|
136
|
Maier JA, Mariotti M, Albini A, Comi P, Prat M, Comogilio PM, Soria MR. Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int J Cancer 1996; 65:168-72. [PMID: 8567112 DOI: 10.1002/(sici)1097-0215(19960117)65:2<168::aid-ijc7>3.0.co;2-x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Kaposi's sarcoma is a highly vascularized multifocal tumor which frequently appears as a complication of HIV infection. It has been suggested that a disorder in the cytokine network may contribute to the development of the disease. We examined the expression of several cytokines in human sporadic Kaposi's-sarcoma specimens, as well as in spindle cells cultured from human lesions, and consistently found high levels of expression of hepatocyte growth factor (HGF). In addition, human lesion-derived spindle cells synthesize and secrete biologically active hepatocyte growth factor and express the hepatocyte-growth-factor receptor (c-MET). Moreover, elevated levels of transforming growth factor beta 1 (TGF beta 1) mRNA were found in lesions of human sporadic Kaposi's sarcoma and in lesion-derived spindle cells which also over-express urokinase. Since HGF, TGF beta 1 and urokinase are all involved in capillary-vessel organization, dysregulation of these interacting agents may play a role in the initiation and/or progression of Kaposi's sarcoma, stimulating the growth of spindle cells and recruiting endothelial cells into the lesion.
Collapse
|
137
|
Lefrère JJ, Mariotti M. Use of digoxigenin-labelled probes for the detection of B19 parvovirus DNA in batches of blood products. Cell Mol Biol (Noisy-le-grand) 1995; 41:985-8. [PMID: 8595378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Being thermostable and non lipid-enveloped, the B19 parvovirus cannot be destroyed by the chemical and physical treatments presently used to inactivate lipid-enveloped viruses such as HIV, hepatitis C and B viruses in plasma derivatives. A polymerase chain reaction assay was used to detect B19 parvovirus DNA. Amplified products were detected through a non-radioactive technology based on the use of a digoxigenin-labelled probe. B19 parvovirus DNA was detected in 20% of the studied batches of factor coagulation concentrates and in none of the albumin batches.
Collapse
|
138
|
Lunel F, Mariotti M, Cresta P, De la Croix I, Huraux JM, Lefrère JJ. Comparative study of conventional and novel strategies for the detection of hepatitis C virus RNA in serum: amplicor, branched-DNA, NASBA and in-house PCR. J Virol Methods 1995; 54:159-71. [PMID: 8530567 DOI: 10.1016/0166-0934(95)00037-u] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The aim of this study was to compare the sensitivity and specificity of conventional procedures (in-house one-stage polymerase chain reaction (PCR) and in-house nested PCR) and of new technologies (rTth DNA polymerase (Amplicor), branched-DNA, NASBA (nucleic acid amplification system)) for the qualitative detection of hepatitis C virus (HCV) RNA in serum of HCV-infected individuals. Serum samples from 37 anti-HCV-positive individuals (15 with a normal alanine aminotransferase (ALT) level, 22 with an elevated ALT level) and 10 anti-HCV-negative individuals as negative controls were studied. A second panel, including 9 diluted serum samples (from 1/10 to 1/100,000) was constituted to establish the differences of sensitivity of the 5 procedures with small quantities of HCV RNA in the serum. The anti-HCV-positive individuals with elevated ALT gave positive results with all 5 procedures. In patients with a normal ALT level, the assays with the highest sensitivity were Amplicor, NASBA and nested RT-PCR, followed by one-stage RT-PCR, then branched-DNA. One false-positive result was observed with Amplicor, and two with in-house nested PCR. On diluted samples, Amplicor, NASBA and nested PCR appeared more sensitive than one-stage PCR and branched-DNA. It is concluded that new procedures have satisfactory sensitivity and specificity and could advantageously replace the conventional PCR procedures for the routine qualitative detection of serum HCV RNA.
Collapse
|
139
|
Guadagnucci A, Tornaboni D, Vignali G, Mariotti M, Cincinelli A, Vignale L. [Neuroleptic malignant syndrome. A case report]. Minerva Med 1995; 86:327-30. [PMID: 7478078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
A lethal case of neuroleptic malignant syndrome in a 42-year-old woman with a history of bipolar psychiatric disorder under treatment with haloperidol is reported. The patient, hospitalized many times in the past for psychiatric treatment, was then admitted for treatment of a relapse of the disease during a exceedingly hot period. The patient complained of hallucinations and stomach ache. It was necessary to increase the dose of haloperidol to 2 mg, 3 times a day, and to give a single dose of perphenazine enanthate 100 mg. All tests proved normal except for CPK 274 U/l and urea 14 mg/dl. On hospital day 2, went into coma with high temperature, diaphoresis, polyuria, leucocytosis (WBC count 15,440 U/mm3), urea 7 mg/dl, LDH 425 U/l, Na 114 mEq/l, K 2.5 mEq/l. The rapid improvement following hypertonic saline treatment encouraged a diagnosis of water intoxication. On hospital day 7, continuing with the haloperidol treatment, the patient developed a high temperature and deterioration torpor. On hospital day 9, the patient went back into coma with temperature over 40 degrees C (104 degrees F), with fine myoclonia most visible on the face, and muscular rigidity. The CPK, rose from 5,169 to 28,060 U/l in less than 24 hours; the serum myoglobin rose to 41,000 ug/l. On day hospital 11 developed renal, cardiac and respiratory insufficiency. The picture deteriorated and dantrolene was no longer of use in controlling the fever. Then with a fever of over 42 degrees (108 degrees F) and the CPK at 50,000 the patient died. The autopsy demonstrated widespread rhabdomyolysis, a picture of widespread aspecific shock in all organs and picture of myoglobin-induced tabular necrosis of the kidney.
Collapse
|
140
|
Meyohas MC, Morand-Joubert L, Van de Wiel P, Mariotti M, Lefrère JJ. Time to HIV seroconversion after needlestick injury. Lancet 1995; 345:1634-5. [PMID: 7783549 DOI: 10.1016/s0140-6736(95)90139-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
141
|
Lefrère JJ, Mariotti M, De la Croix I, Lerable J, Thauvin M, Burnouf T, Folléa G. Albumin batches and B19 parvovirus DNA. Transfusion 1995; 35:389-91. [PMID: 7740609 DOI: 10.1046/j.1537-2995.1995.35595259148.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND B19 parvovirus (B19) may be transmitted iatrogenically by blood, and its prevalence in blood donations is estimated at 1 in 3,300 to 1 in 50,000. As a large number of blood donations make up the plasma pools used to produce plasma derivatives, even a virus as rare as B19 in a population of blood donors may result in the frequent contamination of plasma batches. The percentage of albumin batches containing B19 DNA has never been determined. STUDY DESIGN AND METHODS The presence of B19 DNA was investigated by a polymerase chain reaction assay (with a primer pair in the VP1 region) in a total of 12 and 17 batches of 4- and 20-percent albumin, respectively, from two different manufacturers. RESULTS No B19 DNA was detected in the batches tested. CONCLUSION The current fractionation process used to obtain these albumin preparations is seen to allow the efficient degradation and/or elimination of B19.
Collapse
|
142
|
Morand-Joubert L, Mariotti M, Reed D, Petit JC, Lefrere JJ. Correlation between viral DNA load and serum anti p19 antibody concentration in symptomless human T-lymphotropic virus type-I (HTLV-I)-infected individuals. Int J Cancer 1995; 60:156-9. [PMID: 7829207 DOI: 10.1002/ijc.2910600203] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In order to determine whether serum anti-human T-cell lymphotropic virus type I (HTLV-I) antibody concentration is correlated with cellular viral DNA load, these 2 biological parameters were established in 22 symptomless HTLV-I carriers. The proviral copy (PVC) number was determined through quantificative polymerase chain reaction. Specific antibody titers were determined by Western blot with the end-point dilution method; the quantification of each antibody was performed through ScanBlot by determination of the peak height of each Western-blot band. A positive correlation was observed between the PVC number and the titer of total antibodies. When the association between the peak height of each antibody and the PVC number was studied, a significant positive correlation was observed only with anti-p 19. Further evaluation through follow-up studies of symptomless HTLV-I individuals is needed to clarify the value of anti-HTLV-I antibody titer as a predictor of disease progression.
Collapse
|
143
|
Chevret S, Kirstetter M, Mariotti M, Lefrère F, Frottier J, Lefrère JJ. Provirus copy number to predict disease progression in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994; 169:882-5. [PMID: 7907643 DOI: 10.1093/infdis/169.4.882] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
To evaluate the prognostic value of provirus copy number through quantitative DNA polymerase chain reaction (PCR) in early stages of human immunodeficiency virus type 1 (HIV-1) infection, 42 untreated and asymptomatic HIV-1-seropositive subjects with baseline CD4+ cell counts > 200 x 10(6)/L were included in a prospective study and followed over a median of 27 months. Disease progression was defined as decrease in CD4+ cells to < 200 (14 events). At enrollment, provirus copy number was associated with CD4+ cell count and percentage, serum IgA, and p24 antigenemia. Elevated provirus copy number above 20 allowed identification of patients at high risk of a subsequently decreasing CD4+ cell count, even after adjusting for baseline CD4+ cell count (P = .003). Measuring provirus copy number by PCR at early stages of HIV-1 infection could offer a useful early means to predict progression to AIDS.
Collapse
|
144
|
Abstract
A transfusional B19 parvovirus infection may have severe consequences in immunocompromised hosts. The presence of B19 DNA was investigated with a polymerase chain reaction (PCR) assay in 30 batches of solvent/detergent-treated clotting factor concentrates (12 batches of factor VIII, 16 batches of factor IX, 1 batch of factor VII, and 1 batch of PPSB). B19 DNA was detected in 6 (20%) batches, including 3 factor VIII and 3 factor IX concentrates. Because of the frequency of B19 DNA in batches of clotting factors, measures to prevent transfusional risk of B19 infection via these blood products are justified, especially in recipients immunocompromised by HIV infection.
Collapse
|
145
|
Mariotti M, Wattel E, Lefrère F, Demange F, Lefrère JJ. Polymerase chain reaction procedure for rapid diagnosis of HIV infection. AIDS 1993; 7:1680-1. [PMID: 8286083 DOI: 10.1097/00002030-199312000-00024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
146
|
Abe F, Albrow M, Amidei D, Anway-Wiese C, Apollinari G, Atac M, Auchincloss P, Azzi P, Baden AR, Bacchetta N, Badgett W, Bailey MW, Bamberger A, de Barbaro P, Barbaro-Galtieri A, Barnes VE, Barnett BA, Bauer G, Baumann T, Bedeschi F, Behrends S, Belforte S, Bellettini G, Bellinger J, Benjamin D, Benlloch J, Bensinger J, Beretvas A, Berge JP, Bertolucci S, Biery K, Bhadra S, Binkley M, Bisello D, Blair R, Blocker C, Bodek A, Bolognesi V, Booth AW, Boswell C, Brandenburg G, Brown D, Buckley-Geer E, Budd HS, Busetto G, Byon-Wagner A, Byrum KL, Campagnari C, Campbell M, Caner A, Carey R, Carithers W, Carlsmith D, Carroll JT, Cashmore R, Castro A, Cervelli F, Chadwick K, Chapman J, Chiarelli G, Chinowsky W, Cihangir S, Clark AG, Cobal M, Connor D, Contreras M, Cooper J, Cordelli M, Crane D, Cunningham JD, Day C, DeJongh F, Dell'Agnello S, Dell'Orso M, Demortier L, Denby B, Derwent PF, Devlin T, DiBitonto D, Dickson M, Drucker RB, Einsweiler K, Elias JE, Ely R, Eno S, Errede S, Etchegoyen A, Farhat B, Frautschi M, Feldman GJ, Flaugher B, Foster GW, Franklin M, Freeman J, Frisch H, Fuess T, Fukui Y, Garfinkel AF, Gauthier A, Geer S, Gerdes DW, Giannetti P, Giokaris N, Giromini P, Gladney L, Gold M, Gonzalez J, Goulianos K, Grassmann H, Grieco GM, Grindley R, Grosso-Pilcher C, Haber C, Hahn SR, Handler R, Hara K, Harral B, Harris RM, Hauger SA, Hauser J, Hawk C, Hessing T, Hollebeek R, Hölscher A, Hong S, Houk G, Hu P, Hubbard B, Huffman BT, Hughes R, Hurst P, Huth J, Hylen J, Incagli M, Ino T, Jensen H, Jessop CP, Johnson RP, Joshi U, Kadel RW, Kamon T, Kanda S, Kardelis DA, Karliner I, Kearns E, Keeble L, Kephart R, Kesten P, Keup RM, Keutelian H, Kim D, Kim SB, Kim SH, Kim YK, Kirsch L, Kondo K, Konigsberg J, Kordas K, Kovacs E, Krasberg M, Kuhlmann SE, Kuns E, Laasanen AT, Lammel S, Lamoureux JI, Leone S, Lewis JD, Li W, Limon P, Lindgren M, Liss TM, Lockyer N, Loreti M, Low EH, Lucchesi D, Luchini CB, Lukens P, Maas P, Maeshima K, Mangano M, Marriner JP, Mariotti M, Markeloff R, Markosky LA, Matthews J, Mattingly R, McIntyre P, Menzione A, Meschi E, Meyer T, Mikamo S, Miller M, Mimashi T, Miscetti S, Mishina M, Miyashita S, Morita Y, Moulding S, Mueller J, Mukherjee A, Muller T, Nakae LF, Nakano I, Nelson C, Neuberger D, Newman-Holmes C, Ng JST, Ninomiya M, Nodulman L, Ogawa S, Paoletti R, Papadimitriou V, Para A, Pare E, Park S, Patrick J, Pauletta G, Pescara L, Piacentino G, Phillips TJ, Ptohos F, Plunkett R, Pondrom L, Proudfoot J, Punzi G, Quarrie D, Ragan K, Redlinger G, Rhoades J, Roach M, Rimondi F, Ristori L, Robertson WJ, Rodrigo T, Rohaly T, Roodman A, Sakumoto WK, Sansoni A, Sard RD, Savoy-Navarro A, Scarpine V, Schlabach P, Schmidt EE, Schneider O, Schub MH, Schwitters R, Sciacca G, Scribano A, Segler S, Seidel S, Seiya Y, Sganos G, Shapiro M, Shaw NM, Sheaff M, Shochet M, Siegrist J, Sill A, Sinervo P, Skarha J, Sliwa K, Smith DA, Snider FD, Song L, Song T, Spahn M, Spies A, Sphicas P, Denis RS, Stanco L, Stefanini A, Sullivan G, Sumorok K, Swartz RL, Takano M, Takikawa K, Tarem S, Tartarelli F, Tether S, Theriot D, Timko M, Tipton P, Tkaczyk S, Tollestrup A, Tonnison J, Trischuk W, Tsay Y, Tseng J, Turini N, Ukegawa F, Underwood D, Vejcik S, Vidal R, Wagner RG, Wagner RL, Wainer N, Walker RC, Walsh J, Watts G, Watts T, Webb R, Wendt C, Wenzel H, Wester WC, Westhusing T, White SN, Wicklund AB, Wicklund E, Williams HH, Winer BL, Wolinski J, Wu DY, Wu X, Wyss J, Yagil A, Yasuoka K, Ye Y, Yeh GP, Yi C, Yoh J, Yokoyama M, Yun JC, Zanetti A, Zetti F, Zhang S, Zhang W, Zucchelli S. Measurement of the dijet mass distribution in pp-bar collisions at sqrt s =1.8 TeV. PHYSICAL REVIEW. D, PARTICLES AND FIELDS 1993; 48:998-1008. [PMID: 10016336 DOI: 10.1103/physrevd.48.998] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
147
|
Joubert L, Meyohas MC, Ollivier I, Frottier J, Petit JC, Mariotti M, Lefrère JJ. Viral load in symptomatic primary HIV-infection. AIDS 1993; 7:1127-8. [PMID: 8397953 DOI: 10.1097/00002030-199308000-00018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
148
|
Lefrère JJ, Mariotti M, Trepo C, Li JS, Lunel F, Frangeul L, Letourneur F, Laporte JP, Jullien AM. Testing for HCV-RNA in commercial intravenous immunoglobulins. Lancet 1993; 341:834-5. [PMID: 8096039 DOI: 10.1016/0140-6736(93)90615-n] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
149
|
de Montalembert M, Wattel E, Lefrère F, Mariotti M, Agis F, Ferrer-le-Coeur F, Girot R, Lefrère JJ. Human T-cell lymphotropic virus type I and II DNA amplification in seropositive and seronegative at-risk individuals. Transfusion 1993; 33:106-10. [PMID: 8430447 DOI: 10.1046/j.1537-2995.1993.33293158040.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
To determine the presence or the absence of human T-lymphotropic virus type I and/or II (HTLV-I/II) DNA in at-risk individuals who were persistently negative for specific serologic assays, polymerase chain reaction with two primer pairs in common and conserved regions of HTLV-I and -II genomes was used. Seronegative individuals at risk for HTLV-I/II infection (15 heterosexual partners of seropositive individuals, 17 breastfed children born to HTLV-I-infected mothers, 47 multiply transfused patients, 22 intravenous drug users) were studied (n = 101); 35 seropositive individuals and 25 seronegative low-risk individuals were used as positive and negative controls, respectively. No positive polymerase chain reaction was observed in the seronegative at-risk individuals or in the negative controls. Positive controls gave positive results with at least one primer pair in all cases except one. A latent HTLV-I/II infection with a persistently negative serologic test for HTLV-I/II seems unlikely.
Collapse
|
150
|
Lefrère JJ, Mariotti M, Wattel E, Lefrère F, Inchauspe G, Costagliola D, Prince A. Towards a new predictor of AIDS progression through the quantitation of HIV-1 DNA copies by PCR in HIV-infected individuals. Br J Haematol 1992; 82:467-71. [PMID: 1419830 DOI: 10.1111/j.1365-2141.1992.tb06446.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The proviral copy (PVC) number in peripheral blood mononuclear cells (PBMCs) of human immunodeficiency virus (HIV)-infected individuals was measured by a quantitative polymerase chain reaction (PCR) assay to determine over time the relation between the viral load and the evolution towards the disease in HIV-infected people: 67 anti-HIV-1 positive individuals (60 stage II/III, 7 stage IV) were studied. The mean PVC number per 1.5 x 10(5) PBMCs in stage II/III individuals (14.4 +/- 14.2) and in stage IV individuals (32.2 +/- 22.9) was significantly different (P < 0.02). PVC number was inversely correlated to the CD4 lymphocyte count (P < 0.01). In the logistic regression, the PVC number was a better marker of evolution towards the disease than the CD4 lymphocyte count. The mean proportion of HIV-infected PBMCs in stage IV individuals and in stage II/III individuals was 1/4606 and 1/10714, respectively.
Collapse
|